TAGRISSO as monotherapy is indicated for: – the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. – the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.